FDA Approves 10 New Precision Cancer Treatments in 12 Months

Cancer treatment just got smarter, and patients across the country are getting access to therapies that work with their body instead of against it.

The FDA approved 10 new molecularly targeted cancer treatments over the past 12 months, according to the latest American Association for Cancer Research report. These precision therapies identify and attack specific molecules driving cancer growth, causing less damage to healthy cells than traditional treatments.

Among the breakthroughs is vepdegestrant, approved in May 2026 for certain breast cancer patients. It represents the first FDA-approved PROTAC drug, a revolutionary class that essentially tricks cancer cells into destroying themselves by hijacking their own protein disposal system.

Another game changer came in September 2025 when imlunestrant won approval for breast cancer patients whose disease had stopped responding to hormone therapy. Both drugs target a specific mutation called ESR1, demonstrating how precision medicine matches treatments to each patient's unique cancer blueprint.

Lung cancer patients gained three new options targeting HER2 and EGFR mutations, while ovarian cancer patients got access to relacorilant, the first treatment to block glucocorticoid receptor signaling in platinum-resistant cases. For children with the rare and aggressive diffuse midline glioma, dordaviprone became the first systemic therapy ever approved.

These advances come with better testing too. The FDA approved companion diagnostics alongside many treatments, including the Guardant360 CDx test that identifies which breast cancer patients will benefit from the new therapies. These tests use tumor tissue or blood to determine if a cancer carries the specific genetic alteration a drug targets, sparing patients from ineffective treatments and unnecessary side effects.

The Ripple Effect

The explosion in precision treatments is transforming cancer care across America. Oncologists can now test a patient's tumor, identify its genetic drivers, and match them with therapies designed for their specific cancer type. This personalized approach means more patients are getting treatments that actually work for them.

The shift is creating momentum in cancer research too. As scientists identify more cancer-driving mutations, drug developers are racing to create targeted therapies. Blood cancer patients gained new options with ziftomenib for certain acute myeloid leukemias, while prostate cancer treatment expanded to include more patients who can benefit from existing targeted drugs.

Access remains a challenge, with testing and treatments not reaching all patients equally. But the rapid pace of innovation shows the medical community's commitment to closing these gaps while pushing precision medicine forward.

More than 2.1 million Americans will be diagnosed with cancer in 2026, making these advances deeply personal for families nationwide.